返回 
加入收藏
吉西他滨不同给药方案联合奥沙利铂治疗复发转移性胆管癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 吉西他滨不同给药方案联合奥沙利铂治疗复发转移性胆管癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察吉西他滨不同给药方案联合奥沙利铂治疗复发转移性胆管癌的疗效和安全性。方法：100例复发转移性胆管癌患者随机分为A组（50例）和B组（50例）。A组患者给予注射用吉西他滨1 000 mg/m2，d1、8，固定静脉滴注30 min+注射用奥沙利铂130 mg/m2，d1，静脉滴注。B组患者给予注射用吉西他滨1 000 mg/m2，d1、8，固定输注速率10 mg/（m2·min）+注射用奥沙利铂（用法用量同A组）。两组均以3周为1个疗程，至少行2个疗程治疗。观察两组患者的临床疗效及不良反应发生情况；随访3年，观察两组患者总生存时间和无进展生存时间。结果：两组患者均至少完成2个疗程治疗。B组患者客观缓解率、疾病控制率均显著高于A组，总生存时间、无进展生存时间均显著长于A组，但B组患者Ⅲ～Ⅳ级血小板下降发生率、白细胞下降发生率均显著高于A组，差异均有统计学意义（P＜0.05）。结论：吉西他滨固定输注速率给药方案联合奥沙利铂用于复发转移性胆管癌患者在控制病情进展、延长生存时间、改善远期预后方面均显著优于吉西他滨固定滴注时间给药方案，但用药后可能会增加血液相关不良反应的发生风险。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of different gemcitabine dosage regimens combined with oxaliplatin in the treatment of recurrent metastatic cholangiocarcinoma. METHODS： A total of 100 patients with recurrent metastatic cholangiocarcinoma were randomly divided into group A（50 cases） and B（50 cases）. Group A was given Gemcitabine hydrochloride for injection 1 000 mg/m2，d1、8， for fixed drip time 30 min+Oxaliplatin for injection 130 mg/m2，d1， intravenously. Group B was given gemcitabine 1 000 mg/m2，d1、8，with fixed infusion speed of 10 mg/（m2·min）+ Oxaliplatin for injection （same usage and dosage as group A）. A treatment course lasted for 3 weeks， and both groups received 2 courses. Clinical efficacies and toxic reaction of 2 groups were observed， and total survival time， progression-free survival time of 2 groups were followed up for 3 years. RESULTS： Both groups completed at least 2 courses of treatment. The objective remission rate and disease control rate of group B were significantly higher than those of group A； total survival time and progression-free survival time of group B were significantly longer than those of group A. The incidence of Ⅲ-Ⅳ degree thrombocytopenia and leucopenia in group B were significantly higher than group A， with statistical significance（P＜0.05）. CONCLUSIONS： Gemcitabine dosage regimen of fixed infusion speed combined with Oxaliplation is better than Gemcitabine dosage regimen of fixed drip time for recurrent metastatic cholangiocarcinoma patients in controlling the disease progression， prolonging the survival time and improving the long-term prognosis， but may increase the risk of blood related ADR. |
| 期刊： | 2017年第28卷第27期 |
| 作者： | 吴燕丽，曾晖，王智勇 |
| AUTHORS： | WU Yanli，ZENG Hui，WANG Zhiyong |
| 关键字： | 吉西他滨；固定滴注时间；固定输注速率；胆管癌；复发转移性；疗效；安全性 |
| KEYWORDS： | Gemcitabine； Fixed drip time； Fixed infusion speed； Cholangiocarcinoma； Recurrent metastatic； Therapeutic efficacy； Safety |
| 阅读数： | 1674 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
